This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

GlaxoSmithKline (GSK) is to collaborate with the Francis Crick Institute, a new powerhouse of academic- and charity-funded biomedical research based in London. The new partnership is expected to ...

GSK has brought its message about the risks of antimicrobial resistance (AMR) to commuters in London. The drugmaker worked with its partner the Fleming Initiative to tell people traveling through ...

Teva Pharmaceutical Industries Ltd. ADR 26.47% $18.82B ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Arexvy is an RSV vaccine currently authorised in the US and a further 35 countries. Credit: MargJohnsonVA/Shutterstock. GlaxoSmithKline (GSK) has received approval ...

A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, positioning both companies to compete for that market and laying down a marker for ...

GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...